92 related articles for article (PubMed ID: 5333877)
21. [The morphologic composition of peripheral blood following intra-arterial infusion of 5-fluorouracil and alkylating preparations in stomach cancer patients].
Chernyĭ VA
Vopr Onkol; 1970 Apr; 16(4):61-4. PubMed ID: 4989339
[No Abstract] [Full Text] [Related]
22. [Therapy of multiple myeloma. Study of hospital patients: 81 cases in 16 years' observation].
Monti G; Cereda UG; Pessina E; De Micheli N; Grisetti GC; Invernizzi F
Minerva Med; 1983 Feb; 74(5):155-63. PubMed ID: 6828250
[TBL] [Abstract][Full Text] [Related]
23. [Increased apoptosis of peripheral blood leukocytes correlates with leukopenia after high-dose chemotherapy].
Chukhlovin AB
Vopr Onkol; 1999; 45(4):384-6. PubMed ID: 10532096
[TBL] [Abstract][Full Text] [Related]
24. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
25. Autologous platelet collection and storage to support thrombocytopenia in patients undergoing high-dose chemotherapy and circulating progenitor cell transplantation for high-risk breast cancer.
Torretta L; Perotti C; Pedrazzoli P; Dornini G; Viarengo G; Livraghi A; Noris P; Da Prada GA; Balduini CL; della Cuna GR; Salvaneschi L
Vox Sang; 1998; 75(3):224-9. PubMed ID: 9852411
[TBL] [Abstract][Full Text] [Related]
26. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG
Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282
[TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
28. [Cytostatic treatment of lymphogranulomatosis. Experiences with ibenzmethyzine, cyclophosphamide and vinblastine sulfate].
Schubert JC; Martin H
Munch Med Wochenschr; 1968 Jan; 110(2):97-100. PubMed ID: 5695132
[No Abstract] [Full Text] [Related]
29. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A
Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509
[No Abstract] [Full Text] [Related]
30. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
[No Abstract] [Full Text] [Related]
31. Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037).
Hansen HH; Selawry OS; Muggia FM; Walker MD
Cancer Res; 1971 Mar; 31(3):223-7. PubMed ID: 4926242
[No Abstract] [Full Text] [Related]
32. [Experience with high dosage cytostatic "high single dose" therapy of malignant tumors].
Zerna M; Wolff H
Bruns Beitr Klin Chir (1971); 1966 Mar; 212(2):146-53. PubMed ID: 5994826
[No Abstract] [Full Text] [Related]
33. High-dose carboplatin, cyclophosphamide, etoposide with hematological growth factors, without stem cell support in patients with advanced cancer.
Recchia F; De Fillipis S; Piccinini M; Rea S
Anticancer Res; 2003; 23(5b):4141-7. PubMed ID: 14666615
[TBL] [Abstract][Full Text] [Related]
34. [First clinical experiences with ultrahigh single doses of cyclophosphamide].
Schmitz G; Gross R
Med Welt; 1967 Apr; 16():985-9. PubMed ID: 5585096
[No Abstract] [Full Text] [Related]
35. [Regression of rat sarcoma 45 at single administration of sarcolysine, asalin and asalei].
Syrkin AB; Solenov VN
Farmakol Toksikol; 1969; 32(6):723-6. PubMed ID: 5381606
[No Abstract] [Full Text] [Related]
36. Phase II trial cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma.
Campbell M; Baker LH; Opipari M; Al-Sarraf M
Cancer Treat Rep; 1981; 65(9-10):897-9. PubMed ID: 7196800
[TBL] [Abstract][Full Text] [Related]
37. [Studies on the administration of massive doses of endoxan in pulmonary neoplasms].
Górecki R; Brodziak R; Gondorowicz K; Stanek S
Gruzlica; 1969 Mar; 37(3):251-4. PubMed ID: 4182112
[No Abstract] [Full Text] [Related]
38. Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience.
Cornwell GG; Pajak TF; McIntyre OR; Kochwa S; Dosik H
Cancer Treat Rep; 1982 Mar; 66(3):475-81. PubMed ID: 7060036
[TBL] [Abstract][Full Text] [Related]
39. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
[TBL] [Abstract][Full Text] [Related]
40. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S
Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
